FDAClass IIApril 30, 2025

Duloxetine Delayed-Release Capsules USP recall: Nitrosamine Impurity

Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L., Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922, NDC# 51991-748-10

Why was Duloxetine Delayed-Release Capsules USP recalled?

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

What should I do if I have this product?

The recall is ongoing. Follow the firm and FDA instructions.

What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.

Is my product affected?

Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.

Which lot codes, UPCs or models are affected?

Lot # 240987C, exp. date 04/2027 241014C, exp. date 04/2027

Product
Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L., Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922, NDC# 51991-748-10
Recalling firm
Breckenridge Pharmaceutical, Inc
Quantity
16,473 bottles
Distribution
US Nationwide.
Recall date
April 30, 2025
Classification
Class II
Status
Ongoing
Agency
FDA (drug)
Open FDA enforcement record Latest recalls